Log in

CVE:EBNEpicore BioNetworks Stock Price, Forecast & News

Add
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average Volume29,654 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Epicore BioNetworks Inc. (Epicore) develops, manufactures and markets specialty biotechnology, biochemical and nutrition products. Epicore specialty biochemical products are mixtures of specialty organic, inorganic and biochemical ingredients that facilitate microbe and plant growth. Some Epicore products (such as its EPIZYM-AGP COMPLETE) stimulate algae growth, an important property in shrimp and bivalve hatcheries that grow algae as animal food. Some of its products (such as EPIZYM-BGM) support microbe growth for customers who grow-up an Epicore microbial ecosystem at their location. Some Epicore biochemical products stimulate plant growth to increase plant yield and environmental stress resistance. The third Epicore product group is specialty animal feeds. These products are an extension of its microbial growth media expertise and are primarily used in aquaculture. Its EPIFEED -LHF and EPILITE liquid shrimp larval feeds are tools to help hatchery managers raise postlarval shrimp.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.52 out of 5 stars


Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
CUSIPN/A
CIKN/A
Phone+1-609-2679118

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive EBN News and Ratings via Email

Sign-up to receive the latest news and ratings for EBN and its competitors with MarketBeat's FREE daily newsletter.

Epicore BioNetworks (CVE:EBN) Frequently Asked Questions

Has Epicore BioNetworks been receiving favorable news coverage?

Headlines about EBN stock have been trending somewhat negative on Saturday, according to InfoTrie. The research group identifies negative and positive news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Epicore BioNetworks earned a news impact score of -1.1 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news aboutEpicore BioNetworks.

What other stocks do shareholders of Epicore BioNetworks own?

Who are Epicore BioNetworks' key executives?

Epicore BioNetworks' management team includes the following people:
  • William P. Long, President, Chief Executive Officer, Chief Operating Officer, Director
  • Russell Rosenzweig, Chief Financial Officer, Company Secretary
  • Robert Stephen Poulton, Non-Executive Chairman of the Board
  • Donald R. Siemens, Director
  • Stefan Zaphiriou Zarifi, Director
  • Alan C. Savage, Independent Director

What is Epicore BioNetworks' stock symbol?

Epicore BioNetworks trades on the Canadian Venture Exchange (CVE) under the ticker symbol "EBN."

How do I buy shares of Epicore BioNetworks?

Shares of EBN and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

What is Epicore BioNetworks' official website?

The official website for Epicore BioNetworks is epicorebionetworks.com.

How can I contact Epicore BioNetworks?

Epicore BioNetworks' mailing address is 4 Lina Ln, EASTAMPTON, NJ 08060-5414, United States. The company can be reached via phone at +1-609-2679118.

This page was last updated on 5/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.